REAL-HTN: A Real-world Study of the Effectiveness of Angiotensin Receptor-Neprilysin Inhibitor Therapy in Hypertensive Patients in the United Arab Emirates (clinicaltrials.gov) - Oct 22, 2026 - P=N/A | N=500 | Recruiting | Sponsor: Novartis Pharmaceuticals | Not yet recruiting ➔ Recruiting
Enrollment open • Real-world evidence • Cardiovascular • Hypertension
|